Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohns Disease

ISSN： 0012-6667

Source： Drugs, Vol.64, Iss.16, 2004-01, pp. : 1767-1777

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Toxicity of infliximab in the course of treatment of Crohn’s disease

By Bratcher Jason M Korelitz Burton I

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 9-16

Informa Healthcare

Access to resources Recommend Favorite

Economic Implications of Biological Therapies for Crohns Disease: Review of Infliximab

By Bodger Keith

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 875-888

Adis International

Access to resources Recommend Favorite

TNF- antagonists for the treatment of Crohn’s disease

By Kam L.Y. Targan S.R.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 615-622

Informa Healthcare

Access to resources Recommend Favorite

Recent developments in the pharmacological treatment of Crohn’s disease

By Srinivasan Radhika Lichtenstein Gary R

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 4, 2004-04 ,pp. : 373-391

Informa Healthcare

Access to resources Recommend Favorite

Severe myalgia associated with mesalazine treatment in a child with Crohn’s disease

By Peršić Mladen Palčevski Goran Slavić Irena Vlahović-Palčevski Vera

European Journal of Clinical Pharmacology, Vol. 63, Iss. 3, 2007-03 ,pp. : 315-317

Springer Publishing Company

Access to resources Recommend Favorite